Commentary|Articles|June 5, 2026

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

Fact checked by: Chris Ryan

Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.

The upcoming 2026 EHA Congress marks a pivotal point for leukemia and lymphoma research, as many of this year’s top presentations are centered around how novel approaches like CELMoDS and bispecific antibodies can move standard-of-care regimens away from chemotherapy and toward treatments with reduced toxicity burdens.

Related to this article

EHA 2026 | Image Credit: © Curie - stock.adobe.com

July 9th, 2026

Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

July 16th, 2026

Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

EHA 2026 | Image Credit: © Tongpoon - stock.adobe.com

July 13th, 2026

Dive Into Key Data and Presentations From EHA 2026

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

Cancer | Image Credit: © catalin - stock.adobe.com

July 11th, 2026

Revisit Every OncLive On Air Episode From June 2026

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Follicular Lymphoma | Image Credit: © ArtificialHorizons - stock.adobe.com

July 6th, 2026

Epcoritamab Plus Lenalidomide/Rituximab Wins EU Approval for R/R Follicular Lymphoma

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

Melanoma | Image Credit: © Maris - stock.adobe.com

July 20th, 2026

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

Allo-HSCT | Image Credit: © LASZLO - stock.adobe.com

July 20th, 2026

Older Age Is Independently Associated With Inferior Survival After PTCy-Based Unrelated Donor HSCT in Hematologic Malignancies

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

DLBCL | Image Credit: © Bipul Kumar - stock.adobe.com

July 20th, 2026

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.